Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 26, 2017

Acucela begins enrolment in Phase IIa study of emixustat hydrochloride to treat Stargardt disease

US-based clinical-stage ophthalmology company Acucela, a subsidiary of Kubota Pharmaceutical, has begun enrolment for its Phase IIa study of emixustat hydrochloride (emixustat) to treat Stargardt disease.

US-based clinical-stage ophthalmology company Acucela, a subsidiary of Kubota Pharmaceutical, has begun enrolment for its Phase IIa study of emixustat hydrochloride (emixustat) to treat Stargardt disease.

Vitamin A is recycled in the eye through a process known as the visual cycle.

Emixustat controls the visual cycle by preventing a key enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65).

A slowed visual cycle limits availability of vitamin A derivatives to formation of toxic vitamin A byproducts such as A2E and related compounds.

"This is an important therapeutic development for patients with Stargardt Disease."

The Phase IIa study will be conducted as a multicentre, randomised, masked trial intended to determine pharmacodynamics and the safety and tolerability of emixustat in subjects diagnosed with macular atrophy secondary to Stargardt disease.

The study will enrol about 30 patients across four to six clinical sites in the US who will be randomly assigned to one of three treatment arms in a 1:1:1 ratio.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The subjects will receive an oral administration of dosages of emixustat in 2.5mg, 5mg, and 10mg on a once-daily basis in the evening for one month.

University Hospital in Basel Switzerland and Stargardt Disease Natural History Study (PROGSTAR) study director Dr Hendrik Scholl said: “This is an important therapeutic development for patients with Stargardt Disease.

“Emixustat addresses a well-understood mechanism that leads to toxic accumulation of material underneath the retina linked to visual loss in Stargardt disease and therefore is a promising compound for this debilitating disease.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU